Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cybin Inc. Common Shares (NY:CYBN)

7.450 +0.200 (+2.76%)
Official Closing Price Updated: 8:00 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
40 41 Next >
Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression
Cybin Inc. 
Via Benzinga
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
Via Benzinga
Compass Pathways, Seelos Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 2.83% at $1.09 LOSERS: 
Via Benzinga
7 Psychedelics Stocks to Buy for a Big Drug Boom
These are the seven psychedelics stocks to buy in September. PSIL, ATAI, CMPS, CYBN, ENVB, GHRS and MNMD can make great investments 
Via InvestorPlace
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD
Via Investor Brand Network
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Small Pharma, Biomind Labs Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 27.51% at $0.18 
Via Benzinga
How Psychedelics Startups Are Improving Their Resilience
Via Investor Brand Network
Largest Psychedelic Compound-Based Drug Stocks On A Roll - Up 50% Since End Of June
The Psychedelic Compounds-Based Drug Stocks Index went up 9.8% this week and is now up 49.5% since the end of June albeit down 32.6% YTD. 
Via Talk Markets
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 3.61% at $1.00 LOSERS: 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector
Via Investor Brand Network
Israeli Study identifies Bacterial Footprint in PTSD Sufferers
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 17.87% at $1.22 
Via Benzinga
How Meditation, Psychedelics Can Boost Healing
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From August 23, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 5.33% at $14.24 
Via Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 10.34% at $0.16 
Via Benzinga
FT-104: Field Trip’s Latest Psychedelic Drug Candidate
Via Investor Brand Network
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 29.35% at $0.14 LOSERS: 
Via Benzinga
Why Bed Bath & Beyond Is Trading Lower By Over 40%, Here Are 55 Stocks Moving In Friday's Mid-Day Session
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. 
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
  
Via Benzinga
Study Suggests LSD May Boost Learning, Memory by Enhancing Neural Plasticity
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From August 17, 2022
  
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Partner Receive Required Schedule I License from DEA for First-in-Human Clinical Trial
Via Investor Brand Network
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S. 
Via Benzinga
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From August 16, 2022
  
Via Benzinga
These Depression Players Are Top Picks For $400B Mental Healthcare Market, Says Analyst
HC Wainwright expects COMPASS Pathways Plc (NASDAQ: CMPS) and Cybin Inc (NYSE: CYBN) to be leaders in the emerging $400 billion mental healthcare market. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders
Via Investor Brand Network
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.